@article{Galtier_Vercellino_Chartier_Olivier_Tabouret-Viaud_Mesguich_Di Blasi_Durand_Raffy_Gros_Madelaine_Meignin_Mebarki_Rubio_Feugier_Casasnovas_Meignan_Thieblemont_2023, place={Pavia, Italy}, title={Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells}, volume={108}, url={https://haematologica.org/article/view/haematol.2021.280550}, DOI={10.3324/haematol.2021.280550}, abstractNote={<p>The aim of this study was to evaluate the prognostic impact of the F-fluorodeoxyglucose positron emission tomography response at 1 month (M1) and 3 months (M3) after anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a multicenter cohort of 160 patients with relapsed/refractory large B-cell lymphomas (R/R LBCL). In total, 119 (75%) patients reached M1 evaluation; 64 (53%, 64/119) had a complete response (CR); 91% were Deauville Score (DS) 1-3. Progressionfree survival (PFS) and overall survival (OS) were significantly worse in patients with DS-5 at M1, than in patients with DS 1-3 (PFS hazard ratio [HR]=6.37, 95% confidence interval [CI]: 3.5-11.5 vs. OS HR=3.79, 95% CI: 1.7-8.5) and DS-4 (PFS HR=11.99, 95% CI: 5.0-28.9 vs. OS HR=12.49, 95% CI: 2.8-55.8). The 1-year PFS rates were 78.9% (95% CI: 58.9-89.9) for DS-4 at M1, similar to 67.3% (95% CI: 51.8-78.8) for patients with DS 1-3 at M1, very different to 8.6% (95% CI: 1.8-22.4) for DS-5, respectively. Only eight of 30 (26%) patients with DS-4 progressed. Response at M3 evaluated in 90 (57%) patients was prognostic for PFS with lower discrimination (HR=3.28, 95% CI: 1.5-7.0; P=0.003) but did not predict OS (HR=0.61, 95% CI: 0.2-2.3; P=0.45). Patients with a high baseline total metabolic tumor volume (TMTV) &gt;80 mL had worse PFS (HR=2.05, 95% CI: 1.2-3.5; P=0.009) and OS (HR=4.52, 95% CI: 2.5-8.1; P&lt;0.001) than patients with low TMTV. Multivariable analyses identified baseline elevated lactate dehydrogenase, DS-5, CAR T cells at M1 for PFS and baseline elevated lactate dehydrogenase, TMTV &gt;80 mL, and DS-5 at M1 for OS. In conclusion, baseline TMTV and response at M1 strongly predicts outcomes of patients with R/R LBCL undergoing CAR T-cell therapy.</p&gt;}, number={1}, journal={Haematologica}, author={Galtier, Jean and Vercellino, Laetitia and Chartier, Loic and Olivier, Pierre and Tabouret-Viaud, Claire and Mesguich, Charles and Di Blasi, Roberta and Durand, Amandine and Raffy, Léo and Gros, François-Xavier and Madelaine, Isabelle and Meignin, Veronique and Mebarki, Miryam and Rubio, Marie-Thérèse and Feugier, Pierre and Casasnovas, Olivier and Meignan, Michel and Thieblemont, Catherine}, year={2023}, month={Jan.}, pages={171-180} }